Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
famitinib
- Development stage
- Phase 3
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Famitinib is an orally bioavailable small molecule tyrosine kinase inhibitor developed by Jiangsu Hengrui Medicine. It targets and inhibits multiple receptor tyrosine kinases (RTKs) that are dysregulated in various tumors, including stem cell factor receptor (c-Kit), vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1/2/3), platelet-derived growth factor receptor (PDGFR), and FMS-like tyrosine kinases Flt1 and Flt3. By inhibiting these RTKs, famitinib disrupts tumor angiogenesis and proliferation, leading to tumor regression in cancers overexpressing these targets. It has been investigated primarily for advanced solid tumors such as colorectal cancer, renal cell carcinoma, gastrointestinal stromal tumors, non-small cell lung cancer, triple negative breast cancer, cervical cancer, endometrial cancer, neuroendocrine tumors and others.
- Brand names
- famitinib
- Other names
- famitinib maleateFamitinib, (Z)
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on famitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on famitinib.